Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

Triumvira Immunologics USA, Inc. is an American company located in Austin, TX, with subsidiaries in Canada, that develops and manufactures novel T cell therapies for cancer. Paul Lammers has been the CEO of the firm since 2018.\nThe company says this about itself: Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira��s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon�� Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.

EngMab SARL operates as a biotechnology company. It focuses on cancer immunotherapy and hematological malignancies and solid tumors. The company was founded by Klaus Strein in 2013 and is headquartered in Pfäffikon, Switzerland.

Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Shanghai Longyao Biotech Co., Ltd. engages in the provision of health management services. It focuses on the innovative and development of biotechnology such as tumor immune cell technology,\nstem cell technology, cell storage technology, and anti-aging technology. Its business scope includes\ntechnology development, technical consulting, technology transfer, and technical services of biotechnology; and import and export of goods and technology. The company was founded on September 16, 2013 and is headquartered in Shanghai, China.,

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.

Biositu Jiangsu Gene Biotechnology Co., Ltd., established on 2014-10-14, Business scope includes licensed projects:Offshore trade operation;Experimental animal production;Experimental animal management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology promotion and application services;Medical Research and Experimental Development;Technology Import and Export;Import and export agency;rental service(Licensed rental services not included);Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Promab Biotechnologies, Inc. is a private company headquartered in Richmond, CA, that develops and commercializes recombinant proteins & custom monoclonal antibodies. The firm was founded by Jim Howell Qian.\nThe company says this about itself: ProMab has been an expert in the antibody development field for 19 years, and has been steadily introducing innovative CAR-T/NK cell technology platforms to serve our clients in the immuno-oncology field. The company aims to out-license antibodies validated in CAR-T cell technology in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study. ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of CAR-T/NK cell for life science and biologics development. ProMab offers licenses to its existing antibodies and CAR-T/NK cell platform IP in multiple fields of immuno-oncology.

MorphoSys AG is a therapeutic antibody company based in Martinsried, Germany. The company claims to have more than 100 drugs in its wider pipeline, being investigated for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also maintains an internal pipeline with antibodies in preclinical and clinical development.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Shine-On BioMedical Co., Ltd. engages in the research, development, manufacture, and sale of anti-cancer products. It offers antibody anti-cancer drugs and nucleic acid anti-cancer drugs. The company was founded on April 6, 2021 and is headquartered in Taichung, Taiwan.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Italmatch Chemicals majors in the production of phosphorus derivatives, giving it a unique strength and leading position in the international market. Although a relatively small company, compared to its main competitors, Italmatch Chemicals has earned the respect and trust, over a period of years, of such Multinationals leaders in their sectors, with particular regard to lubricant oil additives (L.O.A.), plastic & polymers flame retardant additives (F.R.) and other various industrial applications. The wide sector already encompassed by Italmatch Chemicals is destined to expand even larger thanks to its historical ambition of growth. The ability to combine the reliability of tradition with the opportunities offered by modern technology, implemented by an expert and dynamic management, results in Italmatch Chemical’s unparalleled creativity, competence and Customers satisfaction. By focusing on today’s dynamic world of specialty chemicals and its expanding horizons, Italmatch Chemicals offers advanced and effective solutions based largely, but not exclusively, on phosphorus derivatives. Careful environmental concern stands to witness the Company long term commitment to the market, as the technologically advanced systems adopted in its Spoleto plant stand to prove, with particular respect to the optimisation of environmental impact and increased safety. For these reasons the Company has recently obtained the ISO 14001:2004 Environmental Certification, and is operating according to both an Environmental Management System as well as a Safety Management System, both subject to periodical revisions and audits.